Pfizer Drugs - Search News

Pfizer, Obesity Drug

Pfizer Wins Obesity Drug Battle, With Assist by Trump’s FTC

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.

· 3h

Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer

· 1d · on MSN

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

· 1d

Pfizer’s obesity win is new formula for pharma M&A

DUBLIN, Nov 10 (Reuters Breakingviews) - Pfizer’s (PFE.N) takeover triumph shows how “America First” is infecting mergers and acquisitions in the drug industry.

· 19h

Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B

· 1d

Novo Nordisk shares rise after dropping Metsera bid

Becker's Hospital Review

The Trump administration’s drug pricing deals, explained

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

STAT

The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's also taking on a lot of risk.

11m

Where Will Pfizer Be in 3 Years?

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.